Allos Therapeutics (ALTH) Reports Q2 Profit of 2c/Share
Tweet
Share
E-mailGet Alerts ALTH Hot Sheet
Price: $1.84 --0%
Financial Fact:
Cost of license and other revenue: 866K
Today's EPS Names:
SYRS, EGRX, AIFC, More
Financial Fact:
Cost of license and other revenue: 866K
Today's EPS Names:
SYRS, EGRX, AIFC, More
Join SI Premium – FREE
Allos Therapeutics (NASDAQ: ALTH) reported Q2 EPS of $0.02, $0.16 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.91 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
